Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -649.33% is 233% below its 5-year average of -194.93%, near the low end of its 5-year range (-649.33%–-43.18%).
140.25% below its 12-month average of -270.27%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -157.79%.
RETURN ON ASSETS (ROA)
-649.33%
RETURN ON ASSETS (ROA) AVG TTM
-270.27%
RETURN ON ASSETS (ROA) AVG 3Y
-262.72%
RETURN ON ASSETS (ROA) AVG 5Y
-194.93%
RETURN ON ASSETS (ROA) AVG 10Y
-1353.26%
RETURN ON ASSETS (ROA) AVG 15Y
-127.25%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-140.25%
CURRENT VS 3Y AVG
-147.15%
CURRENT VS 5Y AVG
-233.11%
CURRENT VS 10Y AVG
+52.02%
CURRENT VS 15Y AVG
-410.29%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1914.05%
vs the sector median at left
Processa Pharmaceuticals, Inc.
Market Cap
$4.11M
Return on Assets (ROA)
-649.33%
TTM Avg
-270.27%
3Y Avg
-262.72%
5Y Avg
-194.93%
Market Cap
$4.13M
Return on Assets (ROA)
N/A
TTM Avg
-140.48%
3Y Avg
-390.49%
5Y Avg
-423.69%
Market Cap
$3.97M
Return on Assets (ROA)
-181.89%
TTM Avg
-125.13%
3Y Avg
-74.22%
5Y Avg
-63.39%
Market Cap
$4.27M
Return on Assets (ROA)
-173.86%
TTM Avg
-97.65%
3Y Avg
-65.17%
5Y Avg
-52.25%
Market Cap
$3.85M
Return on Assets (ROA)
-189.43%
TTM Avg
-137.65%
3Y Avg
-200.06%
5Y Avg
-203.62%
Market Cap
$4.44M
Return on Assets (ROA)
-94.96%
TTM Avg
-122.01%
3Y Avg
-81.62%
5Y Avg
-58.26%
Market Cap
$4.55M
Return on Assets (ROA)
-157.28%
TTM Avg
-221.91%
3Y Avg
-169.98%
5Y Avg
-213.74%
Market Cap
$3.62M
Return on Assets (ROA)
-67.51%
TTM Avg
-41.84%
3Y Avg
-44.47%
5Y Avg
-41.13%
Market Cap
$3.74M
Return on Assets (ROA)
-206.55%
TTM Avg
-205.58%
3Y Avg
-343.02%
5Y Avg
-343.02%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | $4.11M | -649.33% | -270.27% | -262.72% | -194.93% |
| GRI Bio, Inc. (GRI)vs › | $4.13M | N/A | -140.48% | -390.49% | -423.69% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.97M | -181.89% | -125.13% | -74.22% | -63.39% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.27M | -173.86% | -97.65% | -65.17% | -52.25% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.85M | -189.43% | -137.65% | -200.06% | -203.62% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.44M | -94.96% | -122.01% | -81.62% | -58.26% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | -157.28% | -221.91% | -169.98% | -213.74% |
| Evogene Ltd. (EVGN)vs › | $3.62M | -67.51% | -41.84% | -44.47% | -41.13% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.74M | -206.55% | -205.58% | -343.02% | -343.02% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.61M | -194.09% | -543.36% | -310.28% | -256.27% |
ROA
-649.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -173.59% |
| 2024-12-31 | -366.96% |
| 2023-12-31 | -192.19% |
| 2022-12-31 | -318.15% |
| 2021-12-31 | -43.18% |
| 2020-12-31 | -75.51% |
| 2019-12-31 | -30.85% |
| 2018-12-31 | -28.49% |
| 2017-12-31 | -62.23% |
| 2016-12-31 | -10379.43% |
| 2015-12-31 | -3215.29% |
| 2014-12-31 | -178.05% |
| 2013-12-31 | -104.45% |
| 2012-12-31 | -62.83% |
| 2011-12-31 | -17.72% |
| 2010-12-31 | -800.00% |
